Your session is about to expire
← Back to Search
ARNI for Systemic Right Ventricle Heart Failure (PARACYS-RV Trial)
PARACYS-RV Trial Summary
This trial is testing whether a new drug, Sacubitril/Valsartan, is better than placebo at improving exercise capacity and reducing neurohormonal activation in people with moderate to severe RV dysfunction.
PARACYS-RV Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPARACYS-RV Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PARACYS-RV Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My heart condition causes no or severe limitations.I have not had a heart attack, stroke, or open-heart surgery in the last 4 weeks.My heart function is moderately affected, or my exercise capacity is less than 80% of what's expected.You have had a heart transplant in the past or are currently waiting for a heart transplant.I experience symptoms like fainting or dizziness with low blood pressure.My kidney function is severely reduced.Your potassium levels are too high.My liver tests are higher than normal.I am taking medication for conditions other than heart failure.My heart's right side is not pumping well, confirmed by an echo or MRI.I am 18 or older and receive care at the Montreal Heart Institute.You have very high pressure in your lungs, which is equal to or higher than the pressure in the rest of your body.You had bad reactions to ACE-inhibitors or ARBs.I have narrowing in the arteries of both my kidneys.I have severe heart valve issues or blood flow problems.My heart's main pumping chamber is on the right side due to a congenital condition.Your kidney function has decreased by more than 35% from the initial screening to the randomization.You have had swelling in the past related to certain blood pressure medications, or have a history of unexplained swelling.I am scheduled for heart surgery, such as tricuspid valve repair.You are not able to do physical activity.
- Group 1: Placebo
- Group 2: Sacubitril/Valsartan
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the present scope of individuals enrolled in this clinical experiment?
"Affirmative. The clinicaltrials.gov registry details that this medical trial, which debuted on March 15th 2022, is currently recruiting volunteer participants. 48 individuals are required to be registered from one location only."
What clinical indications does Sacubitril / Valsartan Oral Tablet typically address?
"Sacubitril / Valsartan Oral Tablet is frequently prescribed to reduce hypesthesia, and can also be used as a primary treatment in the management of cardiovascular mortality and associated events."
Is this research initiative still open to participants?
"Affirmative. Clinicaltrials.gov has data that confirms this experiment opened for recruitment on March 15th 2022 and was most recently altered on April 4th 2022. The research team is looking to register around 48 individuals from 1 site."
What previous research has been conducted on Sacubitril / Valsartan Oral Tablet?
"Currently, 58 studies have been conducted concerning Sacubitril / Valsartan Oral Tablet. 12 of those active investigations are in the third phase and numerous trials for this therapeutic option are found in Winston-Salem, North carolina with a total of 915 sites running these experiments."
Share this study with friends
Copy Link
Messenger